Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05935748 | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | terminated | Phase 2 | 18 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | terminated | Phase 2 | 102 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Nov 10, 2025 |
| clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 82 | Nuvation Bio Inc.INDUSTRY | 2 | Nov 6, 2025 | clinicaltrials |
| NCT04958785 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer(ELEVATE TNBC) | terminated | Phase 2 | 92 | Gilead SciencesINDUSTRY | 6 | Nov 4, 2025 | clinicaltrials |
| NCT02881554 | Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery | terminated | N/A | 41 | University of WashingtonOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | terminated | Phase 1 / Phase 2 | 23 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 31 | HiFiBiO TherapeuticsINDUSTRY | 2 | Oct 22, 2025 | clinicaltrials |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | terminated | Phase 1 | 25 | Incyte CorporationINDUSTRY | 2 | Oct 21, 2025 | clinicaltrials |
| NCT04050462 | Nivolumab Combined With BMS-986253 in HCC Patients | terminated | Phase 2 | 13 | NYU Langone HealthOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. | terminated | Early Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT04363801 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer(DisTinGuish) | terminated | Phase 2 | 247 | Leap Therapeutics, Inc.INDUSTRY | 3 | Oct 9, 2025 | clinicaltrials |
| NCT03901469 | A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer(TNBC) | terminated | Phase 2 | 115 | Zenith EpigeneticsINDUSTRY | 4 | Oct 7, 2025 | clinicaltrials |
| NCT04616547 | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05276492 | Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. | terminated | Phase 1 | 50 | University of ChicagoOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT04108858 | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2025 | clinicaltrials |
| NCT03535506 | Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery(WI223281) | terminated | Phase 2 | 17 | Georgetown UniversityOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 23 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06302400 | Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma(RHEPaiR) | terminated | N/A | 4 | Imperial College LondonOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | terminated | Phase 1 | 9 | PfizerINDUSTRY | 3 | Sep 17, 2025 | clinicaltrials |
| NCT04249622 | Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer | terminated | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | terminated | Phase 1 / Phase 2 | 175 | Bolt Biotherapeutics, Inc.INDUSTRY | 4 | Sep 15, 2025 | clinicaltrials |
| NCT05582018 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures(PANORAMA) | terminated | N/A | 4 | Techsomed Medical Technologies LTDINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05733351 | Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | terminated | Phase 1 | 4 | Emory UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05678257 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | terminated | Phase 2 | 180 | NuCana plcOTHER | 6 | Sep 12, 2025 | clinicaltrials |
| NCT07117409 | Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure(RI-NIVO) | terminated | — | 81 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07166367 | Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer | terminated | Phase 2 | 3 | National Cancer Centre, SingaporeOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT03838367 | Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC | terminated | Phase 1 / Phase 2 | 10 | CytoDyn, Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04502082 | Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) | terminated | Phase 1 | 8 | Eureka Therapeutics Inc.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT03765736 | Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial | terminated | — | 199 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05009979 | 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | terminated | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05451862 | Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.(HOMIE-166) | terminated | N/A | 6 | Terumo Europe N.V.INDUSTRY | 1 | Aug 26, 2025 | clinicaltrials |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | terminated | Phase 1 | 19 | 3B Pharmaceuticals GmbHINDUSTRY | 2 | Aug 24, 2025 | clinicaltrials |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | terminated | Phase 2 / Phase 3 | 11 | University Health Network, TorontoOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05975645 | A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). | terminated | Phase 1 | 29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT04336943 | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load | terminated | Phase 2 | 6 | University of WashingtonOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04141995 | FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer | terminated | Phase 2 | 11 | University of NebraskaOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT02070705 | DCE MRI in Patients With Pancreatic Cancer | terminated | N/A | 77 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT05435352 | Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment(PEAR-TNBC) | terminated | — | 34 | Ourotech, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03316872 | Study of Pembrolizumab and Radiotherapy in Liver Cancer | terminated | Phase 2 | 18 | University Health Network, TorontoOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04042051 | Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer(Panthera) | terminated | Phase 1 | 2 | Cancer Trials IrelandNETWORK | 2 | Jul 22, 2025 | clinicaltrials |
| NCT05300958 | Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT02140021 | Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer | terminated | N/A | 409 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | terminated | Phase 1 | 5 | Craig L Slingluff, JrOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04992507 | Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study | terminated | Phase 2 | 8 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 12, 2025source: clinicaltrials